Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.
Current status
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.
References
+zu+neoadjuvanter+Standardtherapie+bei+TNBC+und+high-risk+lum.+Tumoren+(HR-positiv%2C+Mammaprint+high-risk).jpg)
